SEMBIOSYS EXECUTES $2,500,000 DEBT FINANCING AGREEMENT

A A

SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceutical product candidates and non-pharmaceutical products, today announced the completion of $2,500,000 in new long-term secured debt financing from Oxford Finance Corporation of Virginia. The proceeds will be primarily used to fund the Company's capital asset purchases, including tripling the capacity of the Company's plant growth facilities. The plant growth facility expansion is necessary to provide additional capacity for the ongoing scale-up of the Company's pharmaceutical product candidates.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-21-2005/0004220185&EDATE=)